User profiles for H. J. Aerts

Hugo Aerts

Other name: HJ Aerts
Director AI in Medicine (AIM) @ Harvard-MGB | Professor @ MaastrichtU
Verified email at dfci.harvard.edu
Cited by 53916

Radiomics versus visual and histogram-based assessment to identify atheromatous lesions at coronary CT angiography: an ex vivo study

…, CL Schlett, MT Lu, B Foldyna, B Merkely, HJ Aerts… - Radiology, 2019 - pubs.rsna.org
Background Visual and histogram-based assessments of coronary CT angiography have
limited accuracy in the identification of advanced lesions. Radiomics-based machine learning (…

Radiomic biomarkers to refine risk models for distant metastasis in HPV-related oropharyngeal carcinoma

…, D Goldstein, JR de Almeida, HJ Aerts… - International Journal of …, 2018 - Elsevier
… Fifth, the radiomic features extracted in this study may differ from the original publication from
Aerts et al. (29) because of the use of the recent PyRadiomics platform (50). Last, the use of …

[HTML][HTML] Handcrafted versus deep learning radiomics for prediction of cancer therapy response

A Hosny, HJ Aerts, RH Mak - The Lancet Digital Health, 2019 - thelancet.com
… In this Comment, the list of authors should have included Ahmed Hosny and Hugo J Aerts.
The declarations of interests for Ahmed Hosny and Hugo J Aerts have been added. These …

Radiomics-based machine learning for outcome prediction in a multicenter phase II study of programmed death-ligand 1 inhibition immunotherapy for glioblastoma

…, E Flagg, K Chang, HX Bai, HJ Aerts… - American Journal …, 2022 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Imaging assessment of an immunotherapy response in
glioblastoma is challenging due to overlap in the appearance of treatment-related changes …

Technical challenges in the clinical application of radiomics

FA Shaikh, BJ Kolowitz, O Awan, HJ Aerts… - JCO clinical cancer …, 2017 - ascopubs.org
Radiomics is a quantitative approach to medical image analysis targeted at deciphering the
morphologic and functional features of a lesion. Radiomic methods can be applied across …

Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non–Small-Cell Lung Cancer

RH Mak, G Hermann, HJ Aerts, EH Baldini… - JCO Precision …, 2018 - ascopubs.org
Purpose In 699 patients with locally advanced non–small-cell lung cancer (NSCLC) treated
with radiation therapy as part of combined modality therapy, we compared outcomes among …

Clinical outcomes after lung stereotactic body radiation therapy in patients with or without a prior lung resection

Y Hou, G Hermann, JH Lewis, HJ Aerts… - American Journal of …, 2018 - journals.lww.com
Objectives: Tumor control (TC), toxicity and survival, following stereotactic body radiation
therapy (SBRT) were compared between patients with and without a prior lung resection (PLR). …

Prediction of distant metastases after stereotactic body radiation therapy for early stage non-small cell lung cancer: development and external validation of a multi …

…, T Shafman, CP Gross, JB Yu, HJ Aerts… - Journal of Thoracic …, 2022 - europepmc.org
Objectives Distant metastases (DM) are the primary driver of mortality for patients with early
stage non-small cell lung cancer (NSCLC) receiving stereotactic body radiation therapy (…

Body composition and overall survival in esophageal cancer patients

…, RH Mak, J Lu, A Shafer, MH Rosenthal, HJ Aerts… - Cancer Research, 2021 - AACR
Aim: We studied body composition throughout the first year after diagnosis and its association
with overall survival (OS) among esophageal cancer patients. Methods: We utilized …

Soluble CD163: a marker molecule for monocyte/macrophage activity in disease

HJ Møller, H Aerts, H Grøbæk… - … Journal of Clinical …, 2002 - Taylor & Francis
By immunoprecipitation we have identified a soluble plasma form of CD163 (sCD163), the IL-6
inducible macrophage-receptor for clearing haptoglobinhaemoglobin complexes. A …